University of Colorado Cancer Center group shows CPT1A may be necessary for ovarian cancer spread, chemo-resistance. Moves toward clinical trial of CPT1A inhibitor, etomoxir, against chemo-resistant ovarian cancer.
Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, "... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor," says lead researcher.
“Two independent sources with the same scientific finding make you think it’s true,” says Jean Mulcahy-Levy, MD, investigator at CU Cancer Center and associate professor in the CU School of Medicine Department of Pediatrics.
Could medicines that activate the immune system protect against COVID-19 infection?
Of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.
University of Colorado Cancer Center study presented at the 2020 Gastrointestinal Cancers Symposium shows patients with locally advanced rectal cancer receiving lower-than-recommended doses of neoadjuvant chemotherapy in fact saw their tumors shrink more than patients receiving the full dose.
University of Colorado Cancer Center study shows healthy form of the leukemia-causing gene MLL may push pluripotent stem cells (which have proven difficult to use in human patients) to become durable hematopoietic stem cells (which are usable in patients, but have until now been impossible to make).
Due in part to advanced surgical techniques, more effective medicines, and a multidisciplinary approach to treating the disease, University of Colorado Cancer Center is able to operate on 30+ percent of pancreatic cancer patients, nearly double the national average.
Study shows Colorado drug SVC112 stops production of proteins that cancer stem cells need to survive and grow
University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion cancers, in addition to the HER2/EGFR cancers for which the drug was originally designed.
Article recently published in Aesthetic Surgery Journal formalizes the treatment strategy for this diagnosis, offering clear guidelines for plastic and oncologic surgeons.
University of Colorado Cancer Center study published in the journal Oncogene shows that while estrogen doesn’t directly affect triple-negative breast cancer cells, it can affect surrounding brain cells in ways that promote cancer cell migration and invasiveness.
While overall rates of colorectal cancer are down, the rate of young people getting the disease is up 22 percent over two decades. International leaders meet in Colorado to set the research agenda to figure out why.
University of Colorado Cancer Center study shows that doctors may be underestimating the risk of and thus under-treating stage I and II breast cancers diagnosed within 10 years of childbirth.
CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Turning off protein metabolism kills these cells.
Navitoclax plus A-1210477 not only killed melanoma cells, but also killed the melanoma initiating cells (aka cancer stem cells) that often resist therapy.
University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."
A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right